{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:25:34Z","timestamp":1773851134137,"version":"3.50.1"},"reference-count":42,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Transarterial chemoembolization (TACE) is an established image-guided, minimally invasive therapy for unresectable hepatocellular carcinoma (HCC). However, post-embolization hypoxia often triggers compensatory angiogenesis and an immunosuppressive microenvironment, limiting long-term efficacy. We hypothesized that the immediate image-guided hepatic arterial infusion (HAI) of a PD-1 inhibitor following TACE could synergistically enhance local tumor control. Methods: In this retrospective, propensity-score-matched study, 226 patients with unresectable HCC (January 2021\u2013June 2024) were analyzed. After 1:1 matching, 84 pairs were included: Study Group (TACE + HAI-nivolumab) and Control Group (TACE alone). Nivolumab (3 mg\/kg) was infused via the hepatic artery under fluoroscopic guidance immediately after embolization. Primary endpoints were overall survival (OS) and progression-free survival (PFS); secondary endpoints included objective response rate (ORR) by mRECIST and changes in serum angiogenesis\/immune biomarkers. Results: The Study Group demonstrated significantly longer median OS (16.2 vs. 12.8 months; HR 0.62, 95% CI: 0.44\u20130.88, p = 0.007) and median PFS (9.8 vs. 6.5 months; p &lt; 0.001). ORR was higher with combination therapy (58.3% vs. 36.9%, p = 0.006). Mechanistically, HAI-nivolumab suppressed the post-TACE surge in VEGF and Ang-2 (p &lt; 0.001) and increased the peripheral CD4+\/CD8+ T-cell ratio. Grade 3\/4 adverse events were comparable between groups (14.3% vs. 10.7%, p = 0.485). Conclusions: The image-guided combination of TACE with immediate HAI of nivolumab is associated with improved survival and tumor response in unresectable HCC. This strategy may counteract the adverse post-embolization microenvironment by simultaneously inhibiting angiogenesis and reactivating local immunity, representing an advanced image-guided combination therapy with strong translational relevance.<\/jats:p>","DOI":"10.3390\/cancers18060978","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:11:12Z","timestamp":1773828672000},"page":"978","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An\u00a0Image-Guided Combination Strategy: Immediate Hepatic Arterial Infusion of Nivolumab Following Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma"],"prefix":"10.3390","volume":"18","author":[{"given":"Sujing","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Oncology, The First Hospital of Hebei Medical University, No. 89 Donggang Road, Yuhua District, Shijiazhuang 050031, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Hospital of Hebei Medical University, No. 89 Donggang Road, Yuhua District, Shijiazhuang 050031, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changwang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Hospital of Hebei Medical University, No. 89 Donggang Road, Yuhua District, Shijiazhuang 050031, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueqian","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Hospital of Hebei Medical University, No. 89 Donggang Road, Yuhua District, Shijiazhuang 050031, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinlei","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Hospital of Hebei Medical University, No. 89 Donggang Road, Yuhua District, Shijiazhuang 050031, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhua","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Hospital of Hebei Medical University, No. 89 Donggang Road, Yuhua District, Shijiazhuang 050031, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"ref_1","unstructured":"European Association for the Study of the Liver (2018). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol., 69, 182\u2013236."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Lok, J., and Agarwal, K. (2021). Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update. Viruses, 13.","DOI":"10.3390\/v13071333"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.3748\/wjg.v25.i32.4614","article-title":"Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions","volume":"25","author":"Inchingolo","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2147\/JHC.S285357","article-title":"Efficacy of Local Treatments for Hepatocellular Carcinoma Involving the Inferior Vena Cava and\/or Right Atrium","volume":"7","author":"Lee","year":"2020","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e0750","DOI":"10.1097\/HC9.0000000000000750","article-title":"The impact of BCLC recommendations on survival for patients with hepatocellular carcinoma","volume":"9","author":"Iavarone","year":"2025","journal-title":"Hepatol. Commun."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Vargas-Accarino, E., Higuera, M., Buti, M., and M\u00ednguez, B. (2024). Hepatitis-C-Related Hepatocellular Carcinoma, Still a Relevant Etiology beyond a Hepatitis C Infection Cure. Cancers, 16.","DOI":"10.3390\/cancers16081521"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"362","DOI":"10.17998\/jlc.2023.08.03","article-title":"The efficacy of treatment for hepatocellular carcinoma in elderly patients","volume":"23","author":"Lee","year":"2023","journal-title":"J. Liver Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"20739","DOI":"10.1038\/s41598-023-48068-7","article-title":"A new model to estimate duration of survival in patients with hepatocellular carcinoma with BCLC intermediate stage","volume":"13","author":"Ninomiya","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.14740\/jocmr2496w","article-title":"The Changes of HIF-1\u03b1 and VEGF Expression After TACE in Patients With Hepatocellular Carcinoma","volume":"8","author":"Liu","year":"2016","journal-title":"J. Clin. Med. Res."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Li, W., Pei, Y., Wang, Z., and Liu, J. (2022). Efficacy of transarterial chemoembolization monotherapy or combination conversion therapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.930868"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Hao, L., Li, S., Ye, F., Wang, H., Zhong, Y., Zhang, X., Hu, X., and Huang, X. (2024). The current status and future of targeted-immune combination for hepatocellular carcinoma. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1418965"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Chen, Y.H., Tsai, C.H., Chen, Y.Y., Wang, C.C., Wang, J.H., Hung, C.H., and Kuo, Y.H. (2023). Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11298-z"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e2300906","DOI":"10.1002\/adhm.202300906","article-title":"Preclinical Development and Validation of Translational Temperature Sensitive Iodized Oil Emulsion Mediated Transcatheter Arterial Chemo-Immuno-Embolization for the Treatment of Hepatocellular Carcinoma","volume":"12","author":"Kim","year":"2023","journal-title":"Adv. Healthc. Mater."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/JS9.0000000000000256","article-title":"TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: A propensity score matching study","volume":"109","author":"Yuan","year":"2023","journal-title":"Int. J. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"17588359211002720","DOI":"10.1177\/17588359211002720","article-title":"Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma","volume":"13","author":"He","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin. Liver Dis."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Cai, Z., Meng, K., Yu, T., Xi, Y., Yuan, Z., Wang, X., Wang, C., Li, L., and Fu, X. (2025). IFN-\u03b3-mediated suppression of ANGPT2-Tie2 in endothelial cells facilitates tumor vascular normalization during immunotherapy. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1551322"},{"key":"ref_19","unstructured":"(2026, January 22). Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, Available online: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): A randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.2147\/JHC.S410967","article-title":"Efficacy of TACE Combined with Lenvatinib Plus Sintilimab for Hepatocellular Carcinoma with Tumor Thrombus in the Inferior Vena Cava and\/or Right Atrium","volume":"10","author":"Ning","year":"2023","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.2147\/JHC.S436211","article-title":"Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma","volume":"10","author":"Long","year":"2023","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"14451","DOI":"10.1007\/s00432-023-05231-x","article-title":"Efficacy and safety of transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors in the treatment of unresectable hepatocellular carcinoma: A systematic review and meta-analysis","volume":"149","author":"Liu","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","article-title":"Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: Results of the PRECISION V study","volume":"33","author":"Lammer","year":"2010","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"72613","DOI":"10.18632\/oncotarget.19997","article-title":"Transarterial chemoembolization (TACE) with degradable starch microspheres (DSM) in hepatocellular carcinoma (HCC): Multi-center results on safety and efficacy","volume":"8","author":"Schicho","year":"2017","journal-title":"Oncotarget"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00270-021-03031-9","article-title":"Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization with or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment","volume":"45","author":"Llovet","year":"2022","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1158\/1078-0432.CCR-18-1254","article-title":"The Role of Angiogenesis in Hepatocellular Carcinoma","volume":"25","author":"Morse","year":"2019","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_30","first-page":"167","article-title":"New insights into mechanisms and interventions of locoregional therapies for hepatocellular carcinoma","volume":"36","author":"Liu","year":"2024","journal-title":"Chin. J. Cancer Res. Chung-Kuo Yen Cheng Yen Chiu"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"16805","DOI":"10.1002\/cam4.6302","article-title":"A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus","volume":"12","author":"Li","year":"2023","journal-title":"Cancer Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e007402","DOI":"10.1136\/jitc-2023-007402","article-title":"Loss of ADAR1 in macrophages in combination with interferon gamma suppresses tumor growth by remodeling the tumor microenvironment","volume":"11","author":"Lin","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"100787","DOI":"10.1016\/j.drup.2021.100787","article-title":"Hypoxia as a driver of resistance to immunotherapy","volume":"59","author":"Kopecka","year":"2021","journal-title":"Drug Resist. Updates"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2217\/fon-2020-0986","article-title":"Immune-based combinations for advanced hepatocellular carcinoma: Shaping the direction of first-line therapy","volume":"17","author":"Rizzo","year":"2021","journal-title":"Future Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Esagian, S.M., Kakos, C.D., Giorgakis, E., Burdine, L., Barreto, J.C., and Mavros, M.N. (2021). Adjuvant Transarterial Chemoembolization Following Curative-Intent Hepatectomy Versus Hepatectomy Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cancers, 13.","DOI":"10.3390\/cancers13122984"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"111266","DOI":"10.1016\/j.ejrad.2023.111266","article-title":"Safety evaluation of combination treatment of drug-eluting bead transarterial chemoembolization and immune checkpoint inhibitors for hepatocellular carcinoma: An increased risk of liver abscess with treatment interval less than one month","volume":"170","author":"Chiu","year":"2024","journal-title":"Eur. J. Radiol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Li, X., Fu, Z., Chen, X., Cao, K., Zhong, J., Liu, L., Ding, N., Zhang, X., Zhai, J., and Qu, Z. (2022). Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.950266"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2147\/JHC.S284440","article-title":"PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects","volume":"8","author":"Rimassa","year":"2021","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jhep.2019.01.027","article-title":"Combined locoregional-immunotherapy for liver cancer","volume":"70","author":"Greten","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12032-024-02309-5","article-title":"The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma","volume":"41","author":"Liu","year":"2024","journal-title":"Med. Oncol."},{"key":"ref_41","unstructured":"(2021). IMMUTACE: A Phase 2 Single-Arm, Open-Label Study of Transarterial Chemoembolization in Combination with Nivolumab Performed for Intermediate-Stage Hepatocellular Carcinoma. Gastroenterol. Hepatol., 17, 6\u201317."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00270-014-0907-0","article-title":"Transarterial chemoembolization for hepatocellular carcinoma with a new generation of beads: Clinical-radiological outcomes and safety profile","volume":"38","author":"Spreafico","year":"2015","journal-title":"Cardiovasc. Interv. Radiol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/6\/978\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:16:51Z","timestamp":1773829011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/6\/978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["cancers18060978"],"URL":"https:\/\/doi.org\/10.3390\/cancers18060978","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]}}}